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The need for comprehensive analysis to compare and combine data across multiple studies in
order to validate and extend results is widely recognized. This paper aims to assess the extent of
data compatibility in the substance abuse and addiction (SAA) sciences through an examination of
measure commonality, defined as the use of similar measures, across grants funded by the
National Institute on Drug Abuse (NIDA) and the National Institute on Alcohol Abuse and
Alcoholism (NIAAA). Data were extracted from applications of funded, active grants involving
human-subjects research in four scientific areas (epidemiology, prevention, services, and
treatment) and six frequently assessed scientific domains. A total of 548 distinct measures were
cited across 141 randomly sampled applications. Commonality, as assessed by density (range of
0–1) of shared measurement, was examined. Results showed that commonality was low and varied
by domain/area. Commonality was most prominent for (1) diagnostic interviews (structured and
semi-structured) for substance use disorders and psychopathology (density of 0.88), followed by
(2) scales to assess dimensions of substance use problems and disorders (0.70), (3) scales to assess
dimensions of affect and psychopathology (0.69), (4) measures of substance use quantity and
frequency (0.62), (5) measures of personality traits (0.40), and (6) assessments of cognitive/
neurologic ability (0.22). The areas of prevention (density of 0.41) and treatment (0.42) had
greater commonality than epidemiology (0.36) and services (0.32). To address the lack of measure
commonality, NIDA and its scientific partners recommend and provide common measures for
SAA researchers within the PhenX Toolkit.
Keywords
Measure commonality; data harmonization; standard measures; gene-environment interactions;
substance use; abuse; addiction
1. INTRODUCTION
The need for comprehensive analysis to compare and combine data across multiple studies
in order to validate and extend results is widely recognized. When a cross-study analysis
includes multiple data sets that lack measure commonality, data harmonization is needed in
order to encompass the data from related, but not identical, measures and protocols. Data
harmonization efforts require thoughtful consideration of what data can/should be combined,
and typically include a time-consuming re-coding step prior to carrying out the cross-study
analysis. While procedures for combining data sets with nonidentical measures are under
active development and represent an important tool (Hussong et al. 2013; Fortier et al.,
2010), greater confidence in construct equivalence (the extent to which a concept assessed
across studies has the same meaning across studies) may result from using common
measures during the data-collection phase. Consequently, greater use of common measures
facilitates pooling of data across multiple independent studies. Such pooling enables
researchers to undertake analyses addressing important research questions that the individual
studies themselves are illequipped to address.
In the addiction sciences, the ability to pool data and perform integrative data analysis is
particularly important and timely. The identification and verification of relatively weak
associations and more complex relations, such as gene-gene and gene-environment
interactions related to addictions, is vastly improved via analysis of larger samples sizes than
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any single study contains or is fiscally feasible to ascertain anew (Agrawal et al., 2012;
Duncan and Keller, 2011; Heath et al., 2011; Sher et al., 2010). The advantages of measure
commonality also apply to intervention, epidemiological, and developmentally informative
studies, including accelerated cohort designs that examine trajectories over a broad age span
during a study (or studies) of short duration (Miyazaki and Raudenbush, 2000).
While it is generally recognized that low levels of measure commonality is problematic in
the addiction sciences, we are aware of no empirical examination of this topic. This paper
examines measure commonality across grants funded by the National Institute on Drug
Abuse (NIDA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA).
Analysis of measures within grants funded by these two institutes – collectively the world’s
largest funding source of research in the field of substance use, abuse, and addiction –
provides a comprehensive and representative picture of the extent of measure commonality
in the field. Following the empirical examination, this paper discusses current efforts to
increase measurement commonality and accelerate scientific discovery, and highlights
important resources for substance abuse and addiction research.
2. METHODS
To estimate the commonality of measures related to substance use, abuse and addiction, a
portfolio analysis was conducted across grants funded by NIDA and NIAAA to identify
occurrences where similar measures were proposed by two or more applications. Data were
extracted from applications of funded, active grants involving human-subjects research in
the areas of epidemiology, prevention, services, and treatment. These areas were targeted
because we assumed that grant applications within each of these areas would study related
topics, and that there would be a tendency for similarity in the constructs and measures.
Furthermore, investigators in these areas increasingly recognize the importance of data
comparability, interoperability, and integration across multiple studies (Curran and Hussong,
2009), particularly in the area of gene-environment interactions (Bennett et al., 2011; Bierut,
2011; Cornelis et al., 2010; Duncan and Keller, 2011), a research portfolio that is largely
housed within the epidemiology domain.
2.1 Sampling and procedure
Our intention was to sample a reasonably sized and representative number of R01 grants that
were active as of late March/early April, 2011 (N=829). This date corresponds with the
initiation of the NIDA supplement to the PhenX Toolkit to create the Substance Abuse and
Addiction (SAA) collection, described later in this manuscript, and is intended to serve as a
baseline assessment of measure commonality. After numbering each of the 829 grants, we
sampled 141 using a random number generator program in Microsoft Excel; this sample size
was sufficient to give a 7.5% margin of error at the 95% confidence level.
2.2 Coding and data analysis
The 141 grant applications were manually examined to code the proposed measures of all
constructs related to substance use, abuse, and addiction. For estimating reliability, a sample
of applications (n=14) was randomly selected for coding by a second independent
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researcher, resulting in a total of 190 observations of measures used. These observations
were compared for agreement between two coders. A total of 162 observations matched
exactly, reflecting 85.3% agreement.
The number of applications proposing to use each measure was calculated separately by
scientific domain and scientific area. For the scientific domains, we focused on the six most
frequently assessed in SAA research: (1) diagnostic interviews (structured and semi-
structured) for substance use disorders and psychopathology, (2) scales to assess dimensions
of substance use problems and disorders, (3) scales to assess dimensions of affect and
psychopathology, (4) measures of substance use quantity and frequency, (5) measures of
personality traits, and (6) assessments of cognitive/neurologic ability. There were four
scientific areas defined by administrative branch or program unit: epidemiology at NIDA
(n=28) and NIAAA (n=11), prevention at NIDA (n=23) and NIAAA (n=19), services at
NIDA (n=17) and NIAAA (n=5), and treatment at NIDA (n=22) and NIAAA (n=16).
The use of common measures was then examined within domain and area. Density of
measurement commonality was calculated and used as a unit of comparison across domain/
area. To calculate this value, the number of distinct measures was divided by the frequency
of uses of measures by applications, then standardized on a scale from 0–1, with 1 being
highly common (1−[(total n distinct measures)/(n uses of all measures)]).
3. RESULTS
A total of 548 distinct measures were cited across the 141 grant applications. This included a
broad range of measures such as the Structured Clinical Interview for DSM Disorders
(SCID; First et al., 1996; Spitzer et al., 1992), Fagerstrom Test for Nicotine Dependence
(FTND; Heatherton et al. 1991), the Multidimensional Personality Questionnaire (MPQ;
Tellegen and Waller, 2008), the Beck Depression Inventory (BDI; Beck et al., 1961), and
the Trail Making Test, parts A and B (TMT; Reitan, 1994). Figure 1 shows the top 10 most
common measures in each of the six most commonly assessed domains. The domain of
diagnostic interviews of substance use disorders and psychopathology had the greatest
commonality (108 uses of 13 unique measures, density of 0.88), followed by the domain of
scales to assess dimensions substance use problems and disorders (136 uses of 41 unique
measures, density of 0.70). More moderate degrees of commonality were observed for the
domain of scales to assess dimensions of affect and psychopathology (190 uses of 59 unique
measures, density of 0.69) and the domain of measures of substance use quantity and
frequency (124 uses of 47 unique measures, density of 0.62). Commonality was more
limited in the personality domain (40 uses of 24 unique measures, density of 0.40) and the
cognitive/neurologic domain (67 uses of 52 unique measures, density of 0.22).
Similarly, there was limited commonality within each area of science (density: 0.32–0.42).
The areas of prevention (251 uses of 149 unique measures, density of 0.41) and treatment
(429 uses of 250 unique measures, density of 0.42) had greater commonality than
epidemiology (343 uses of 221 unique measures, density of 0.36) and services (165 uses of
113 unique measures, density of 0.32). Additional post-hoc analyses revealed high levels of
commonality (density: 0.70–0.81) within certain domains within these scientific areas. In the
Conway et al. Page 4






















areas of epidemiology (0.81), prevention (0.70), and treatment (0.70), the diagnostic
measures of substance use disorders or psychopathology had greater commonality compared
to the other domains. In the services area, the substance use quantity and frequency domain
had the greatest commonality (0.60).
4. DISCUSSION
The analysis revealed a dearth of measure commonality across multiple related areas of
SAA science. Across the areas of epidemiology, prevention, treatment, and services research
funded by NIDA or NIAAA, the use of common measures was rare. An exception was
observed for the assessment of substance use and psychiatric disorders, perhaps because of
the limited number of measures to choose from in this domain. Additional analyses (results
not shown) replicated this general lack of measure commonality in other areas of SAA (e.g.,
clinical neuroscience), further suggesting its pervasiveness. This lack of commonality is not
without consequences. The absence of common measures in SAA impedes cross-study
comparability, replication, and large-scale data integration, the latter of which is paramount
to advancing high-priority areas that require very large sample sizes, including addiction
genomics (Ripke et al., 2013).
Our findings should be considered in light of several study limitations. First, the data were
drawn from applications of funded grants, and there was no attempt to contact investigators
to inquire about the use of measures not mentioned in the applications and/or changes in the
use of proposed measures following funding. Second, measures used by studies not funded
by NIDA or NIAAA were not captured. Third, the sample comprised NIH grants across
related areas of addiction science (epidemiology, treatment, services, and prevention),
suggesting a potential for overestimating measurement commonality in the addiction field.
Fourth, the classification of measures into domains was somewhat crude, as some measures
(e.g., Self-Ratings of the Effects of Alcohol) do not fit neatly into one of the broad domains
and, within a domain, serve different purposes (e.g., unidimensional versus
multidimensional assessments of depression) or target different developmental groups (e.g.,
children vs. adults). Finally, the definition of measure commonality focused on similarity of
measures rather than items/questions within measures; this method would have missed
occasions of commonality when studies using different measures used some of the same
items/questions. Future work will assess and track item-level commonalty, including the
conditions under which it occurs (i.e., different studies using all items from the same
measure, different studies using some items from the same measure, different studies using
the same items albeit from different measures). This analytic approach would directly assess
and monitor item-level commonality, and build upon findings from the current paper.
Overall, these limitations suggest that caution be taken when generalizing and interpreting
the results.
To address the lack of measure commonality documented herein, NIDA and its scientific
partners launched an effort that provides investigators with, via the PhenX Toolkit (https://
www.phenxtoolkit.org/), a common set of tools and resources that allow their work to span
the manifold of SAA areas. As described elsewhere (Hamilton et al., 2011a, 2011b; Maiese
et al., 2013), the PhenX Toolkit is a catalog of well-established, standard measures of
Conway et al. Page 5






















phenotypes and exposures recommended for human-subjects studies across 21 fields of
research, and its development followed a rigorous consensus process led by domain experts
and vetted by the scientific community. To expand the depth and breadth of measures in the
PhenX Toolkit, the SAA project was launched in early 2011, with support from NIDA, to
identify a “Core” collection and six “Specialty” collections recommended for human-
subjects studies in the addiction sciences (see http://grants.nih.gov/grants/guide/notice-files/
NOT-DA-12-008.html). A total of 43 new measures in support of SAA research were added
to the Toolkit in February 2012 (Table 1).
Importantly, we note that pursuit of measure commonality is not to replace specific or
specialized measures crucial to an investigator’s core hypothesis, but to create a common
item set across studies to allow for the comparing and pooling of data. The PhenX Toolkit
and other measure-commonality and data-harmonization efforts and tools will not only
increase research productivity, but will also foment scientific discovery within and beyond
the addiction sciences. There are several other existing tools and initiatives aimed at data-
harmonization and measure-commonality, located in the e-supplementary materials.
Collectively, these efforts reflect an embracing of a “big data” culture of large-scale data
integration, and underscore a growing emphasis on sharing and creating opportunities to
create multi-study linkages. Hand-in-hand with increasing use of common measures is the
need to develop effective mechanisms for data sharing. To date at NIH, a number of data-
sharing efforts have been initiated, which have been included in the Supplementary
Materials1.
The NIH will continue to play a central role in fostering a culture of cooperation, data
sharing, and collaboration. In this sense, measure commonality must be viewed as an
essential component of a larger strategy to marshal investigators to more effectively reap the
benefits of the considerable Federal investment in biomedical and health research to advance
science and improve the nation’s health.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Top 10 Most Common Measures in Six Frequently Assessed Domains
Diagnostic Measures: SCID = Structured Clinical Interview for DSM-IV; CIDI =
University of Michigan Composite International Diagnostic; DIS = Diagnostic Interview
Schedule – based instruments; MINI = Mini-International Neuropsychiatric Interview;
AUDADIS = Alcohol Use Disorder and Associated Disabilities Interview Schedule; ADI =
Adolescent Diagnostic Interview; KSADS = Kiddie Schedule for Affective Disorders and
Schizophrenia; ADI-Parent = Adolescent Diagnostic Interview-Parent; PRISM = Psychiatric
Research Interview for Substance and Mental Disorders; SIDP-IV Structured Interview for
DSM-IV Personality.
Substance Use Disorder Scales: AUDIT = Alcohol Use Disorders Identification Test;
FTND = Fagerström Test for Nicotine Dependence; ADS = Alcohol Dependence Scale;
DRINC = Drinker Inventory of Consequences; RAPI = Rutgers Alcohol Problem Index;
MWS = Minnesota Withdrawal Scale; OCDS = Obsessive Compulsive Drinking Scale;
AUQ = Alcohol Urge Questionnaire; CIWA-Ar = Clinical Institute Withdrawal Assessment
for Alcohol – Revised; NDSS = Nicotine Dependence Syndrome Scale.
Psychopathology Scales: BSI = Brief Symptom Inventory; CES-D = Center for
Epidemiologic Studies Depression Scale; BDI = Beck Depression Inventory; YSR = Youth
Self-Report of the Child Behavior Checklist; CBCL = Child Behavior Checklist; GAIN =
Global Appraisal of Individual Needs; PANAS = Positive and Negative Affect Schedule;
POMS = Profile of Mood States; PEI = Personal Experiences Inventory; ASR = Adult Self-
Report, Adult behavior checklist.
Substance Use Quantity and Frequency Measures: General Q and F = General Quantity
and Frequency Questions; Form 90 = Form 90 from Project Match; MTF = Monitoring the
Future Quantity and Frequency of Substance Use Questions; DDQ = Daily Drinking
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Questionnaire; NSDUH = National Survey of Drug Use and Health Quantity and Frequency
of Substance Use Questions; NHIS = National Health Interview Survey; DUQ = Drug Use
Questionnaire; SUQ = Substance Use Questionnaire; ADAC = Adapted Daily Alcohol
consumption; ADAS = American Drug and Alcohol Survey
Personality Measures: BFI = Big Five Inventory; MPQ = Multidimensional Personality
Questionnaire; SSS = Sensation Seeking Scale (Zuckerman); BSSS = Brief Sensation
Seeking Scale; EIS = Eysenck Impulsivity Scale; NEO FFI = NEO Five Factor Inventory;
EATQ = Early Adolescent Temperament Questionnaire – Revised; AIS = Avoidance and
Inflexibility Scale; Assertiveness = Assertiveness (Gambrill and Richey); BASC =
Behavioral Assessment System for Children.
Cognitive-Neurologic Measures: TMT = Trail Making Test A and B; ANT = Attention
Network Task; DBS = Decisional Balance Scale; Decision Making = Decision making (5-
item scale developed by Botvin, Baker); SRE = Self-Ratings of the Effects of Alcohol; SST
= Stop-signal task; Stroop = Stroop Color and Word Test; WAIS-III = Wechsler Adult
Intelligence Scale III Comprehension Subscale; WISC subtests = Wechsler Intelligence
Scale for Children subtests; WMS = Wechsler Memory Scale.
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Tier 1 19 Current Age; Ethnicity; Gender; Race; Current
Educational Attainment; Current Employment
Status; Current Marital Status; Body Mass Index;
Current Quality of Life; Self-report of Human
Immunodeficiency Virus (HIV) Testing; Tobacco -
Smoking Status; Tobacco - 30-day Quantity and
Frequency; Tobacco - Age of Initiation of Use;
Alcohol - Lifetime Use; Alcohol - 30 Day Quantity
and Frequency; Alcohol - Age at First Use;
Substances - Lifetime Use; Substances - 30 Day
Frequency; Substances - Age at First Use
Tier 2 8 Annual Family Income; Child-Reported Parental
Educational Attainment; Household Roster-
Relationships; Occupation/Occupational History;
Family History of Substance Use Problems;
Internalizing, Externalizing, and Substance Use
Disorders Screener; Peer/Partner Substance Use
and Tolerance of Substance Use; Social Networks
Specialty Areas
Assessment of Substance Use and Substance Use
Disorders
7 Alcohol Breathalyzer; Family History of Substance
Use Problems; Lab-based Urine Drug Analysis;
On-site Urine Drug Screen; Patterns of Substance
Use; Screening and Severity of Substance Use
Problems; Substance Abuse and Dependence - Past
Year
Substance Use-related Co-morbidities and Health-related
Outcomes
8 Behavioral Health Screener; Comprehensive HIV
Risk Assessment; Duration of Abstinence; Health
Quality Index for Economic Evaluations; Self-
Help Involvement; Service Utilization and Cost;
Substance Abuse Treatment, Participation, and
Involvement; Victimization Screener
Substance Use-related Community Factors 8 Cigarette Price; Disapproval of Substance Use;
Perceived Availability of Illegal Drugs and
Alcohol; Perceived Harm of Substance Use; Point
of Sale Environment for Alcohol and Tobacco;
Substance Abuse Treatment Quality; Treatment
Availability and Level of Care; Unmet Need for
Alcohol or Drug Treatment
Substance Use-related Neurobehavioral and Cognitive
Risk Factors
7 Cognitive Flexibility (Dimensional Change Card
Sort); Decision Making (Iowa Gambling Task);
Delayed Reward Discounting (Monetary Choice
Questionnaire); Inhibitory Control (Stop Signal
Paradigm); Laboratory Test of Risk Taking
(Balloon Analogue Risk Task); Motor and
Attentional Impulsivity (Immediate and Delayed
Memory Task); Response Inhibition (Go/NoGo
Task)
Substance Use-related Psychosocial Risk Factors 6 Community Risk and Protective Factors;
Externalizing Problems; Family Risk and
Protective Factors; Peer/Partner Substance Use and
Tolerance of Substance Use; School Risk and
Protective Factors; Sensitivity to Reward and
Punishment; Temperament
Substance-specific Intermediate Phenotypes 5 Acute Subjective Response to Substances -
Current; Acute Subjective Responses to
Substances - Retrospective; Expectancies -
Alcohol, Tobacco, and Other Substances; Motives
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https://www.phenxtoolkit.org/index.php?pageLink=browse.conceptualgroupsandid=2169andbreadcrumbs=2169
Measure Count Measures
- Alcohol, Tobacco, and Other Substances; Self-
reported Craving
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